The European Commission has approved Biogen's QALSODY® (tofersen), a pioneering treatment for a rare genetic type of ALS.

Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.

Actym Therapeutics revealed that the U.S. FDA allowing the commencement of a Phase 1 clinical trial for its primary drug candidate, ACTM-838.

U.W. FDA recognizes Astellas' resubmitted biologics license application for zolbetuximab and establishes a new target date.

This TROPiCS-04 trial compared the effects of Trodelvy (sacituzumab govitecan-hziy; SG) against single-agent chemotherapy in individuals with metastatic urothelial carcinoma (mUC).

Ivonescimab plus chemotherapy approved by NMPA for 2L+ EGFRm NSCLC in China: HARMONi-A Trial shows positive overall survival trend for the combination.

TransCode Therapeutics Announces Positive Data from Initial Human Trial of New Lead Therapy Candidate, TTX-MC138.

Biohaven administers initial dose of new Trop-2 targeting ADC BHV-1510 to patient with advanced or metastatic epithelial cancers.

Full-Life Technologies Gets FDA Nod for IND Application of 225Ac-FL-020 in Treating Metastatic Castration-Resistant Prostate Cancer.

Jazz Pharmaceuticals plc has reported that the Biologics License Application for zanidatamab, has been accepted and given Priority Review status by the U.S. Food and Drug Administration.

Telix Reports Encouraging rPFS Results from TLX591 rADC Therapy Candidate ProstACT SELECT Trial for Prostate Cancer.

Astellas Pharma Inc. revealed that the U.S. Food and Drug Administration has recognized their resubmission of the Biologics License Application for zolbetuximab.